All-time high in QuickMIC® abstracts at ECCMID 2024
The diagnostics company Gradientech today announces that six QuickMIC® abstracts will be presented at the 34th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Barcelona, Spain 27-30 April 2024.
ECCMID is the world’s premier meeting place for clinical microbiologists and infectious disease specialists, gathering over 14,000 delegates yearly. This year, a record 7,000+ abstracts have been submitted, setting the stage for an exceptional event in April.
At ECCMID 2024, six different abstracts with data from independent European studies will demonstrate that QuickMIC displays highly accurate results compared to state-of-the-art antibiotic susceptibility testing (AST) solutions on the market. The studies have been performed by various leading European hospital laboratories based in markets with different antibiotic resistance situations. The large number of studies and solid results will further strengthen the case of QuickMIC being the premier rapid AST system on the market.
”Gradientech is committed to continuously performing high-quality studies with leading hospitals to demonstrate the exceptional accuracy, precision and speed of the QuickMIC rapid AST system, as well as to prove the benefit in clinical outcome of rapid AST to the patient. It is extremely encouraging to witness the great interest in the study results, evident by the large number of accepted abstracts with QuickMIC data at ECCMID this year. We cannot wait to share the results with the larger community,” says Christer Malmberg, Chief Scientist at Gradientech.
The QuickMIC system’s ultra-rapid and precise AST results enable sepsis patients to receive specific personalised guidance of the right antibiotic and the right dose in record time. The modular design offers affordable scaling possibilities, making QuickMIC attractive to both small and large hospital laboratories. QuickMIC and its Gram-negative panel are CE-marked and commercially available in Europe but not yet available for sale in the United States.
For further information, please contact:
Sara Thorslund, PhD, CEO Christer Malmberg, PhD, Chief Scientist
Tel: +46 736 29 35 80 Tel: +1 919 808 7190
Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance – one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.
Next-generation antimicrobial susceptibility testingTake a look at our E-book